Conserved role of dopamine in the modulation of behavior

Andrés G. Vidal-Gadea and Jonathan T. Pierce-Shimomura*
Section of Neurobiology; The University of Texas at Austin; Austin, TX USA

Dopamine is an ancient signaling molecule. It is responsible for maintaining the adaptability of behavioral outputs and is found across taxa. The following is a summary of the role of dopamine and the mechanisms of its function and dysfunction. We discuss our recent findings on dopaminergic control of behaviors in C. elegans and discuss its potential implications for work in the fields of C. elegans and Parkinson research.

A Ubiquitous Signaling Molecule

The monoamine dopamine is a small signaling molecule that can be synthesized from the amino acid tyrosine by the enzyme tyrosine hydroxylase. In the absence of tyrosine hydroxylase, dopamine can be made inefficiently by tyrosinase (Fig. 1).1,2 The widespread use of dopamine by different taxa hints at its ancient origin. Some photosynthesizing protists have daily vertical migrations in the water column triggered by the presence of daylight. An antagonist dopamine-acetylcholine system has been shown to control this activity by affecting light sensitivity: with dopamine decreasing it.3,4 Dopamine is also found in fruits and vegetables where its oxidation results in the familiar brown spots on ripe bananas.5,6 Its role in plants appears to be as a strong antioxidant, providing protection from lipid peroxidative damage caused by the intense heat and sunlight of the tropics.7 In bacteria, fungi, protozoans, cnidarians, nematodes, arthropods, mollusks, annelids and vertebrates, dopamine seems present wherever it is sought (Fig. 2).8-17

Although the main role of dopamine is in intraorganismal signaling, opportunistic organisms sometimes exploit dopamine signaling for inter-species interactions. For example, mammals release dopamine as part of their systemic response to infection; pathological organisms use this signal in an attempt to survive the immune response. Gram-negative bacteria respond to this dopamine signal by accelerating their division rate often overwhelming the host’s defenses.18 Pathogenic fungi respond to this signal by synthesizing melanin, making them resistant to ionic oxidants released by the host's macrophages.19 Since many fungi use dopamine as a precursor for melanin synthesis, some fungi selectively invade dopamine producing areas of the brain, causing meningitis.20 Other animals have cracked the dopamine code of their prey. Some wasps for example inject dopamine into the cockroach nervous system forcing them to passively host their larvae.21,22

A wealth of specialized receptors has allowed the use of dopamine to be widespread across taxa as well as within organisms where it can modulate diverse processes.23,24 This diversity may have risen through processes of gene duplication and horizontal gene transfers beginning with bacteria.25 In mammals, five serpentine dopamine receptors have been described in two pharmacologically distinct classes. The D1-like receptors (DOP1 and DOP5) act postsynaptically to increase cyclic adenosine monophosphate (cAMP) levels, while D2-like receptors (DOP2, DOP3 and DOP4) act both pre- and postsynaptically to reduce cAMP levels.26-27 In addition to D1- and D2-like receptors, some invertebrates also have ionotropic dopamine receptors.28 The competing regulation of cAMP levels by the different D1-like and D2-like receptor types allows the use of dopamine in the
fine control of behavior. This is particularly effective when rapidly changing environmental forces require the modification of ongoing behavioral patterns, such as during locomotion or during risk-reward evaluations.\(^\text{25}\)

In animals, one of the main roles of dopamine is to act as a behavioral switch in the transition from faster to slower motor patterns. This has been best demonstrated in well-controlled electrophysiological studies of fictive forms of rhythmic locomotion in reduced (semi-intact) preparations. For instance, dopamine slows down locomotion in snails.\(^\text{29}\) Both in sea slugs and in leeches, dopamine inhibits swimming and induces crawling, while in lamprey, zebrafish and crabs it slows down locomotor rhythms.\(^\text{14-17,29}\) However, the role of dopamine in controlling locomotion in these systems has not been demonstrated in freely-behaving animals.

**Dopaminergic Signaling in *C. elegans***

Dopaminergic signaling has been intensely studied in the nematode worm *Caenorhabditis elegans*. Hermaphroditic worms have eight (mechanosensory) dopaminergic neurons (the male has additional neurons but won’t be discussed here). Although developmentally distinct, these neurons are divided into three classes on the basis of their morphology: four CEP neurons innervate the tip of the nose, two ADE neurons innervate the head cuticle, and two posterior PDE neurons innervate the posterior cuticle.\(^\text{53}\)

As in other animals, worm dopaminergic neurons express genes encoding tyrosine hydroxylase (TH/cat-2), dopa decarboxylase (bas-1), vesicular monoamine transporter (*cat-1*), dopamine transporter (*dat-1*), as well as autoreceptors (*dop-2*). The coordinated expression of each of these genes and others that typify differentiated dopaminergic neurons is initiated and maintained throughout life by a terminal selector (EST transcription factor) that binds a 10 base-pair promoter element that is conserved in mammals.\(^\text{31}\) The eight dopamine neurons act both through classic synapses (429 synapses in total) as well as extrasynaptically by releasing dopamine into the worm’s body cavity.\(^\text{32,33}\) All worm dopamine neurons also express the mechanotransduction channel TRP-4 and are thought to be mechanoreceptive.\(^\text{34-37}\) *C. elegans* has D1-like receptor genes (*dop-1* and *dop-4*) and D2-like receptor genes (*dop-2* and *dop-3*) similar to the ones found in mammals (in addition to some unique nematode receptors).\(^\text{25,28,38-40}\)

Depending on the type, dopamine receptors are expressed exclusively in neurons or also in non-neuronal cells.\(^\text{33}\) D1-like receptors are expressed in neuronal and non-neuronal targets alike (e.g., muscle, glia); D2-like receptors are restricted to neurons which is in keeping with a neuroregulatory role.\(^\text{25}\) Notably, dopaminergic neurons express the autoreceptor DOP-2 that operates in negative feedback loops.\(^\text{25}\) The parallel between the dopaminergic systems of *C. elegans* and mammals extends to the role of dopamine in modulation of behavioral patterns by environmental cues, and to processes of learning and memory. A classical example of environmental modulation of behavior via D1- and D2-like receptor interactions comes from studies of DOP-3 and DOP-1 receptors coexpressed in mechanosensory and motor neurons and that antagonistically mediate the decrease in locomotion by well-fed worms as they enter a patch of food.\(^\text{39}\)

Evaluation of cost vs. benefit for environmental cues is a crucial process. In mammals this process is tightly associated with balance between D1- and D2-like pathways whose chemical disruption can lead to addiction.\(^\text{41}\) *C. elegans* also uses dopamine to compare the quality of its environment against its internal physiological state and re-evaluates its responses accordingly. For example, in the presence of food worms will habituate their escape response more rapidly; a behavior presumably mediated by their dopaminergic mechanosensory neurons that detect the texture of the food.\(^\text{42}\) In *C. elegans*, this kind of learning can be in response to both gustatory and odor information.\(^\text{43-46}\) While some forms or learning (e.g., habituation to mechanical stimuli) take place through the D1-like pathway, others (e.g., associative learning) are facilitated by pre-synaptic changes in dopaminergic neurons.\(^\text{47,48}\) Dopaminergic signaling appears to be influenced in *C. elegans* by compounds that are addictive in humans such as ethanol and cocaine.\(^\text{39-51}\)

In addition to learning and memory, dopamine also modulates many behavioral patterns in *C. elegans*, inhibiting many behaviors that are promoted by serotonin.\(^\text{52,53}\) Serotonin promotes a number of behaviors in *C. elegans*: including egg-laying, through its action on command and motor neurons; pharyngeal pumping (feeding), through its action on motor neurons and muscles; and more recently swimming, through yet unspecified targets.\(^\text{52,53}\) Age-related locomotor changes have been correlated with changes in the dopamine/serotonin balance in older worms.\(^\text{54}\)

---

**Figure 1. Synthesis pathway for dopamine.** Dopamine is primarily synthesized by tyrosine hydroxylase (A) but can also be made in its absence (B).\(^\text{2}\)
Our lab has recently discovered a new role for dopamine in transitioning between motor patterns on land and in water. In *C. elegans*, crawling on land consists of slow (~0.5 HZ) dorsoventral body bends of high angular amplitude that result in a persistent “S-like” body shape. By contrast, swimming in water is characterized by alternating dorsoventral body bends of high frequency (~1.5 HZ) and low angular amplitude that result in worms sequentially alternating between “C-like” shapes. While both behaviors propel the animal forward, the spatial patterns of bending forces have been shown to be the result of differential patterns of muscular activity produced by the animal to locomote in environments with distinct drag coefficient ratios.\(^5\)\(^6\) When the speed of the worm is constrained by a range of viscous solutions, *C. elegans* displays discontinuous bouts of crawl- or swim-like kinematics rather than a simple continuous modulation of locomotory kinematics. This result, together with additional experiments that reveal bimodal switching of locomotory patterns, demonstrates that crawling and swimming represent mutually exclusive forms of locomotion, also commonly known as distinct “locomotory gaits.”

Of the three classes of dopaminergic neurons described above, we found that only ADE and PDE were required for worms to transition from swimming to crawling.\(^5\)\(^7\) This is consistent with how ADE and PDE neurons have mechanoreceptive endings on the sides of the worm that could detect firm contact with the ground, while the CEP neurons instead innervate the tip of the nose which the worm typically keeps off the ground. Our finding that both anterior (ADEs) and posterior (PDEs) dopaminergic mechanoreceptor neurons are required during gait transitions could seem surprising—diffusion is thought to be very rapid in such small organisms. In fact, we found that injection of dopamine into the anterior and posterior regions of the worm’s body produced distinct results; with anterior injections alone being able to induce gait transitions.\(^5\)\(^7\) This suggests that (at least while swimming) worms can effectively compartmentalize their pseudocoelomic space. Both ADE and PDE neurons send processes to the anterior half of the body where they would presumptively release dopamine locally and effect a swim-to-crawl transition.

Downstream from the dopamine neurons we found that worms transitioned from distinct swimming to crawling gaits through the D1-like dopaminergic pathway.\(^5\)\(^7\) Elimination of dopamine or D1-like receptor genes (*dop-1* or *dop-4*) caused worms to collapse upon exit from a puddle. While many worms stopped moving altogether for up to 45 min, other worms displayed unproductive crawling often by propagating a single dorsoventral bend from head to tail before stopping or initiating backward locomotion. Gently prodding these worms induced crawling. Conversely, raising dopamine levels caused worms to inappropriately switch from swimming to crawling in water (an effect also dependent on D1-like receptors).\(^5\)\(^7\) In keeping with other behaviors, the transition to crawling depended not only on the balance between D1- and D2-like receptors (as mutants lacking both receptor types showed no phenotype, Fig. 3) but also on the balance between dopamine and serotonin. Altering the balance between these amines by means of exogenous drug application, endogenous photo-uncaging of the amines, or stimulating their release via optogenetic stimulation (of the producing neurons), induced gait transitions between swimming and crawling. Our results suggest that as worms emerge from a puddle, ground contact is sensed through a subset of mechanosensitive dopaminergic neurons. These in turn release dopamine into the anterior body cavity and trigger
crawling through the D1-like pathway. Conversely, immersion in water stimulates release of serotonin and inhibits dopamine release (caused by the removal from the substrate). This last finding is consistent with previous work on the leech where endogenous levels of serotonin were found in association with the induction of swimming behavior. It should be noted that in our experiments we altered the balance between serotonin and dopamine without removing the underlying environmental context. Therefore worms swimming in water, once induced to crawl (by dopamine release), remained nevertheless immersed in water (therefore receiving conflicting sensory information). This could account for the episodic nature of the behavioral inductions, where worms could be seen alternating between swimming and crawling bouts as a result of the conflicting sensory inputs represented by the applied amine and the actual physical environment. Furthermore, under certain experimental conditions crawling waves induced in water failed to propagate all the way to the tail, suggesting that the full production of the behavior likely involves additional control systems as those proposed by other groups.32,59-61

These findings suggest a combinatorial system for behavior selection where synergies between different dopaminergic pathways interact with those between dopamine and other amines. For example, swimming behavior seems to occur by the combined effects of a decrease in dopamine release (brought about by loss of ground contact), and an increase in serotonin release (brought about by entrance into an aquatic medium). It is perhaps through these interactions that dopamine seems to not just trigger one behavioral transition, but rather a whole host of behaviors associated with crawling on land; like foraging, feeding and defecation.62 One interesting method for studying how the balance within dopaminergic signaling pathways and between dopamine and other neurotransmitter signaling systems is maintained is in a comparison between land-grown and liquid-grown C. elegans. As mentioned above, worms entering a liquid environment experience a decrease in dopamine and an increase in serotonin that triggers transition into swimming and the inhibition of crawling as well as many other behaviors like feeding, defecation and egglaying which are crucial for survival. However, in order to survive and reproduce in a liquid environment, worms would need to overcome this aurally-induced shift toward serotonin (by increasing dopamine production, decreasing serotonin production, or a combination of the two) long enough to carry on the afore-mentioned vital functions. In their original description of the dopaminergic system of C. elegans, Sulston et al. reported no less than a 62-fold increase in levels of L-dopa (the precursor of dopamine) for worms grown in liquid culture.13 Thus, it seems that culture of C. elegans in liquid is accompanied by a chronic—and significant—upregulation of dopamine production that may enable temporary reversal of the serotonin-dopamine balance and allow animals to engage in feeding and other vital functions while immersed in liquid.

The dopaminergic effects described above primarily involve feeding and reductions in locomotory rates. These are consistent with other known roles of dopamine. For instance, when worms enter a patch of food (bacteria) dopamine is responsible for a couple of well-characterized behaviors that facilitate food ingestion, namely “basal slowing” and “area-restricted search.” During basal slowing, dopaminergic neurons in non-starved worms are thought to mechanically sense surrounding bacteria and decrease crawling velocity (termed as basal slowing).37 At the same time dopamine is proposed to also increase the turning rate resulting in worms thus remaining in the vicinity of a food source (termed Area Restricted Search).63 Faced with adverse environmental conditions, C. elegans larva enter an alternative developmental stage known as dauer, dopamine has also been implicated in reducing...
locomotor output and causing the characteristic quiescent states of these animals. For example, mutations in the gene encoding the dopamine reuptake transporter dat-1 lead to a buildup of extrasynaptic dopamine resulting in the swim-induced paralysis phenotype (SWIP). Our model of swim induction as the combined effect of a decrease in dopamine release and an increase in serotonin release is consistent with the SWIP phenotype. Here a buildup of endogenously released dopamine in swimming dat-1 mutants would eventually lead to a transition to crawling, termination of swimming and finally paralysis (SWIP).

These findings hint to dopamine as a possible master switch, capable of altering the behavioral state of an animal by inhibiting and promoting sets of motor outputs in a context-dependent way. The great degree of conservation in molecular and functional pathways seems to span across taxa to mammals where the dopaminergic system has been intensely studied due to its role in Parkinson disease.

**Parkinson Disease**

In 1817 James Parkinson described a disease (later renamed by Charcot in his honor) affecting the motor system with tremors, rigidity, bradykinesia and imbalance. Parkinson disease (PD) etiology involves the death of dopaminergic neurons in the substantia nigra pars compacta of the brain. Environmentally, death of dopaminergic neurons can be induced by acute exposure to manganese, by 6-hydroxydopamine (6OHDA), MPTP, or by other toxic species that dopaminergic neurons selectively uptake. Alternatively, mutations in genes involved in dopaminergic signaling can also lead to PD. Examples of mutations known to cause dopaminergic neuron loss include those affecting the LRRK2, PARK2 and SNCA genes. The presence of different alleles for these genes, and the endogenous synthesis of 6OHDA from dopamine may all contribute to the development of PD. During the development of the disease, it is possible that the balance between the D1- and the D2-like dopaminergic pathways becomes compromised as the gradual reduction of dopamine levels is mitigated by postsynaptic compensatory changes. Herein may lie one of the greatest challenges of PD treatment, as merely replacing lost dopamine in the brain (or its precursor L-dopa) does not repair potential receptor imbalances created by the disease. Therefore, L-dopa alone is unable to prevent the eventual onset of secondary motor deficits. Further complicating treatment, differences in dopamine receptor polymorphisms have been shown to result in differential responses to standard treatments. For example, treatment with Levodopa has been shown to upregulate the expression of D1-like (but not D2-like) receptors and is associated with the development of a disorder known as Levodopa-induced dyskinesias (LID). Treatment with both Levodopa and D2-like agonist (derived from non-mammalian systems) seem to mitigate LID supporting the idea that preserving the balance between these two pathways is crucial for recovery. In light of this bleak picture, it is evident that studies in model systems permitting fast genetic and molecular evaluation of pathway dynamics and interactions are necessary to complement ongoing efforts in classical mammalian systems.

In a recent manuscript we introduced a fast, facile behavioral assay capable of asaying potential drugs (or mutations) affecting some of the motor deficiencies associated with loss of dopaminergic signaling during PD. We found that (paralleling findings with Parkinson patients) animals with impaired D1- to D2-like receptor balance exhibited deficits in transitioning between different behaviors. Besides showing remarkable conservation of function from worms to human, our findings suggest that the use of *C. elegans* in Parkinson research could expand to include behavioral approaches, besides the genetic and molecular ones already in use.

**The Future of *C. elegans* in Parkinson Research**

The genetic amenability of *C. elegans*, coupled with the level of conservation in dopaminergic pathway and function has already led to its profitable use in the field of PD research. Many studies have sought to establish *C. elegans* as a valid model system in this field by showing parallels between its dopaminergic system and that of mammals. Overexpression of the human gene encoding α-synuclein (a protein associated with a familiar form of PD) leads to dopamine neuron degeneration in the worm. Work on *C. elegans* has shown that 6OHDA causes degeneration of dopaminergic neurons through DAT-1, and that the chaperone molecule TorsinA can protect against this effect. Automated systems using *C. elegans* can now quickly screen thousands of putative drugs. Fast and economical high-throughput screens have already begun yielding drugs and gene targets that can serve as potential therapeutic approaches for the treatment of human afflictions such as PD.

The remarkable conservation in the dopaminergic pathway and function across phyla strongly hints to the importance of its role in the survival of organisms. In evolutionary terms, no sooner is an organism capable of performing two incompatible tasks than it becomes subservient of the need to determine which one is adaptive in which situation. For Parkinson research, this conservation means that there is much useful information to be gained from studying extra-mammalian dopaminergic systems. The diversity of motor outputs found in the animal kingdom, when compared with the conservation of the systems modulating them evidences how forgiving natural selection can be to one process and how strict to another.

**References**

1. Elsworth JD, Roth RH. Dopamine synthesis, uptake, metabolism and receptors: relevance to gene therapy of Parkinson’s disease. Exp Neurol 1997; 144:4-9; PMID:9126143; http://dx.doi.org/10.1006/exnr.1996.6379.
2. Rius M, Habecker B, Sazanka T, Eisenhofer G, Tian H, Landis S, et al. Catecholamine synthesis is mediated by tyrosinase in the absence of tyrosine hydroxylase. J Neurosci 1999; 19:3519-26; PMID:10212311.
3. Forward RB Jr. Effects of neurochemicals upon a dopamine-like photoreceptor. J Protozool 1977; 24:401-5; PMID:23286.
4. Kiefer DA, Lasker R. Two blooms of Gymnodinium splendens, an unarmored dinoflagellate. Fish Bull USA 1975; 73:675-8.

5. Udenfriend S, Lovenberg W. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

6. Kiefer DA, Lasker R. Two blooms of Gymnodinium splendens, an unarmored dinoflagellate. Fish Bull USA 1975; 73:675-8.

7. Udenfriend S, Lovenberg W. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

8. Kiefer DA, Lasker R. Two blooms of Gymnodinium splendens, an unarmored dinoflagellate. Fish Bull USA 1975; 73:675-8.

9. Udenfriend S, Lovenberg W. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

10. Kiefer DA, Lasker R. Two blooms of Gymnodinium splendens, an unarmored dinoflagellate. Fish Bull USA 1975; 73:675-8.

11. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

12. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

13. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

14. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

15. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

16. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

17. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

18. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

19. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

20. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

21. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

22. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

23. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

24. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

25. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

26. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

27. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

28. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

29. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

30. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

31. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

32. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

33. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

34. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

35. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

36. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

37. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

38. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

39. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

40. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

41. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

42. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

43. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

44. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

45. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

46. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

47. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

48. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

49. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.

50. Carlberg M, Anctil M. Biogenic amines in coelenterates. Acta Pharmacol Toxicol 1971; 29:235-49.
62. Parkinson J. An essay on the shaking palsy. London: Whittingham and Rowland 1817; 1-66.

63. Bouchard M, Mergler D, Baldwin ME, Panisset M. Manganese cumulative exposure and symptoms: a follow-up study of alloy workers. Neurotoxicology 2008; 29:1236-47; http://dx.doi.org/10.1016/j.neurotox.2008.04.013.

64. Breese GR, Traylor TD. Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br J Pharmacol 1971; 42:889-99; PMID:5580702.

65. Langton JW, Palfman J. The case of the frozen addicts. New York: Pantheon Books 1995; 1-309.

66. Pramstaller PP, Schlössmann MC, Jacques TS, Scaravilli F, Escolano C, Pepipani I, et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkinson mutation carriers. Ann Neuroc 2005; 58:411-22; PMID:16163011; http://dx.doi.org/10.1002/ana.20587.

67. Whaley NR, Urri R, Dickson DW, Farber MJ, Wiziele ZK. Clinical and pathological features of families with LRRK2-associated Parkinson's disease. J Neurotransrn Supt 2006; 70:203-20; PMID:16558785; http://dx.doi.org/10.1002/jns.20113.

68. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmund MJ. A role for α-synuclein in the regulation of dopamine biosynthesis. J Neurosci 2002; 22:5069-79; PMID:1943814.

69. Senoh S, Witkop B, Clevering RR, Udenfriend S, 2,4,5-trihydroxyphenethylamine, a new metabolite of 3,4-dihydroxyphenylalanine. J Am Chem Soc 1959; 17:618-9; http://dx.doi.org/10.1021/ja01078a000.

70. Senoh S, Clevering RR, Udenfriend S, Witkop B. Chemical, Enzymatic and Metabolic Studies on the Mechanism of Oxidation of Dopamine. J Am Chem Soc 1959; 81:6236-40; PMID:1943814.

71. Fang-See C, Wyart M, Xie J, Kawai R, Kodger T, Chen S, et al. Biomechanical analysis of gait adaptation in the nematode Caenorhabditis elegans. Proc Natl Acad Sci USA 2010; 107:20323-8; PMID:20138086; http://dx.doi.org/10.1073/pnas.1003106107.

72. Vidal-Gadea AG, Topper S, Young L, Crisp A, Kressin E, Elbel E, et al. Caenorhabditis elegans selects distinct clefting and swimming gaits via dopamine-mediated mechanisms. Proc Natl Acad Sci USA 2011; 108:17504-9; PMID:21969584; http://dx.doi.org/10.1073/pnas.1009371108.

73. Willard AL. Effects of serotonin on the generation of the motor program for swimming by the medicinal leech J Neurosci 1981; 13:96-44; PMID:7288474.

74. Korta J, Clark DA, Gabel CV, Mahadevan L, Samuel ADT. Mechanosensational and mechanical load modulate the locomotor gait of swimming. C. elegans. J Exp Biol 2007; 210:2383-9; PMID:17575043; http://dx.doi.org/10.1242/jeb.004572.

75. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmund MJ. A role for α-synuclein in the regulation of dopamine biosynthesis. J Neurosci 2002; 22:5069-79; PMID:1943814.

76. Ruben A, Kresse J, Kresse A, Sandock A, et al. Similar patterns of mitochondrial vulnerability and pharmacological analysis of neurotransmitters in the medicinal worm: application of C. elegans as a predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders. Neurotherapeutics 2012; 9:393-404; http://dx.doi.org/10.1007/s13311-012-0109-9.

77. Hassamichi S, Rivas RN, Knight AL, Cao S, Caldwell KA, Caldwell GA. Hypothesis-based RNAI screening identifies neuroprotective genes in a Parkinson disease model. Proc Natl Acad Sci USA 2008; 105:728-33; PMID:18132484; http://dx.doi.org/10.1073/pnas.0711039105.

78. Netter NE, Riederer P, Daniel GM, Marsden CD, Marsden CD. Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Proc Natl Acad Sci USA 2002; 99:3264-9; PMID:11867711; http://dx.doi.org/10.1073/pnas.042477999.

79. Cao S, Gelvix CC, Caldwell KA, Caldwell GA. Torin-mediated protection from cellular stress in the dopaminergic neurones of Caenorhabditis elegans. J Neurosci 2005; 25:5801-12; PMID:15829632; http://dx.doi.org/10.1523/JNEUROSCIENCE.5357-04.2005.

80. Red J, Saha S, Westlund B, Perier C, Burnam L, Shuler A, et al. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of α-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem 2005; 280:7268-76; PMID:15929314; http://dx.doi.org/10.1074/jbc.M509102000.

81. Braungart E, Gerlach M, Riederer P, Baumeister R, Hoener MC. Caenorhabditis elegans PAPP model of Parkinson's disease for high-throughput drug screenings. Neurotherapeutics 2004; 1:175-83; PMID:15690897; http://dx.doi.org/10.1016/j.neuro.2004.08.098.
101. Lemieux GA, Liu J, Mayer N, Bainton RJ, Ashrafi K, Werb Z. A whole-organism screen identifies new regulators of fat storage. Nat Chem Biol 2011; 7:206-13; PMID:21390037; http://dx.doi.org/10.1038/nchembio.554.

102. Doitsidou M, Flames N, Lee AC, Boyanov A, Hobert O. Automated screening for mutants affecting dopaminergic-neuron specification in Caenorhabditis elegans. Nat Methods 2008; 5:869-72; PMID:18758453; http://dx.doi.org/10.1038/nmeth.1250.

103. Flames N, Hobert O. Gene regulatory logic of dopamine neuron differentiation. Nature 2009; 458:885-9; PMID:19287374; http://dx.doi.org/10.1038/nature07929.

104. Raan Q, Harrington AJ, Caldwell KA, Caldwell GA, Standaert DG. VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson’s disease. Neuron Dis 2010; 37:330-8; PMID:19850127; http://dx.doi.org/10.1016/j.nbd.2009.10.011.